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ABSTRACT 
Objective: This study was undertaken to determine the bioavailability of ondansetron gel in experimental animals and humans applying UPLC as an 
analytical tool and evaluation of the antiemetic effect of ondansetron gel in cisplatin-induced emesis in rats.  
Methods: Ondansetron gel (F13: sodium alginate 7% w/w) was used, marketed I. V. ondansetron (Zofran) ®
Results: Ondansetron gel (0.5%) showed detectable plasma concentration 22.833±2.17 ng/m1 after ¼ h and 419.55±2.17 ng/ml after 1-h post-
treatment in rabbits and human respectively and concentration was maintained above-reported minimum effective concentration for more than 2.5 
h for rabbits and 7 h for humans compared to 1.75 h after I. V. administration. 
 was chosen as reference. The 
bioavailability study in rabbits was selected as a parallel design using nine healthy rabbits divided into three groups whereas, bioavailability study 
in humans was an open-label, wherein 6 healthy subjects administered ondansetron gel. The potential effect of ondansetron gel was evaluated for 
the prevention of different phases of emesis motivated by exposure to antineoplastic drugs (cisplatin) by determination of body weight loss, water 
and food intake applying kaolin-pica model in rats using seventy-two rats divided into six groups. 
The ondansetron gel significantly reduces all phases of cisplatin-induced emesis and a decrease in body weight, water, and food consumption was 
significantly attenuated. 
Conclusion: Based on the high efficacy of gel on emesis induced by cisplatin, and its high bioavailability, transdermal ondansetron gel could be a 
promising convenient system to prevent nausea and vomiting following administration of antineoplastic drugs.  
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INTRODUCTION 
Ondansetron is a selective 5-HT3
Pharmacokinetic and biopharmaceutical studies of drug products 
are useful tools to investigate the relationship between 
physicochemical properties of the drug and the pharmacological 
effect produced [10]. Measurement of drug concentration in 
biological fluids, such as blood or urine following drug 
administration is considered a direct and efficient method for the 
determination of systemic drug bioavailability [11]. However, 
quantitative measurement of drug concentration in biological fluids 
is not always available or, in other instances, lacks sufficient 
accuracy. In this case, the pharmacological effect of the drug can be 
used as an indirect measure of drug bioavailability [12]. 
 (5-hydroxytryptamine, or serotonin) 
antagonist receptor [1-5]. It is a primary drug utilized to treat, prohibit 
and stop chemotherapy-induced nausea and vomiting (CINV), it is also 
efficient in prevailing postoperative nausea and vomiting (PONV) and 
after radiation therapy-induced nausea and vomiting [6-8]. 
Ondansetron is taken 1–3 times daily, and it is available commercially 
as an oral and disintegrable tablet, solution, and injection [8]. 
Intravenous (IV) route has quick effects, but it confers a local pain and 
for its short half-life, ondansetron requires recurrent administrations. 
Also, oral administration has many disadvantages as it not desirable in 
nausea and vomiting, difficulties occurred in the gastrointestinal tract 
during absorption due to enzymes, food-drug interactions, etc. [8]. 
Subsequently, it is very eligible to develop another delivery system to 
overcome the side effects associated with IV and/or oral dosage forms. 
So, ondansetron transdermal gel was formulated and evaluated from 
previous in vitro and ex vivo studies [9]. Whereas it is especially 
suitable for cancer patients who suffer from frequent episodes of 
vomiting and nausea and thus they cannot keep the oral dosage form 
and intravenous chemotherapy formerly worn out their veins. 
Nausea and vomiting associated with the administration of 
chemotherapeutic drugs are attributed to the activation of serotonin 
type 3 receptors existing in the gastrointestinal tracts and/or central 
nervous system [13-16] due to cellular damage to the intestinal mucosa 
[17]. Cisplatin, a common chemotherapy drug, has many hurtful side 
effects such as the stimulation of nausea, vomiting, anorexia and general 
malaise [18]. Cisplatin was classified as the highest emetic risk group as 
it causes acute and delayed vomiting [19, 20]. So, selective 5-HT3
To evaluate the antiemetic efficacy, different animal models 
including ferrets, dogs, and monkeys have been utilized [25]. 
However, generally, rodents such as mice and rats do not show 
vomiting behaviors, in comparison to the emesis-prone animals such 
as ferrets and dogs. Instead, mice and rats eat non-nutritive 
materials such as kaolin, so-called pica as a phenomenon of vomiting 
reflex, following treatment with poisons or under rotating situation 
[26-30]. It was proposed that increased pica is an illness–response 
behavior of the rat, similar to vomiting in other species and humans 
[26], which can be utilized as a readily-quantifiable behavioral assay 
of deleterious drug effects [27]. 
 
receptor antagonists are very efficient in prohibiting nausea and emesis 
in animals [21, 22] and cancer patients [23, 24].  
Thus, the main adjective of this study was to estimate a comparative 
bioavailability study of ondansetron gel formulation in rabbits and 
healthy human volunteers using intravenous ondansetron, as a 
reference standard applying UPLC as the analytical tool for assessing 
the drug concentration in plasma. Further, the investigation is 
extended to evaluate the potential effect of ondansetron from gel 
formulation for the prohibition of different phases of emesis 
encouraged by exposure to antineoplastic drugs such as cisplatin by 
determination of body weight loss, water and food intake employing 
a kaolin-ingesting pica model in rats. 
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MATERIALS AND METHODS 
Materials 
Ondansetron was kindly provided by (Adwia Co., Cairo, Egypt), 
K3EDTA ampoules (Voma med., Italy). Zofran® I. V. injection 8 mg/4 
ml (Glaxo Smithkline S. A. E. El-Salam City, Egypt). HPLC grade of 
Acetonitrile and methanol (Sigma Chemical Co. St. Louis, Mo, USA). 
Cisplatine®
Methods 
, I. V. vial 10 mg/10 ml (Mylan, France). Sodium alginate 
(The General Chemical and Pharmaceutical Co., Ltd., England). 
Standard rat chow pellets. Kaolin of pharmaceutical grade (Clay, 
naturally hydrated aluminum silicate) was purchased from (EL-
Gomhouria Co., Egypt). Acacia (gum Arabic) (ISO-CHEM, Egypt). All 
chemicals and reagents used were of analytical grade. 
Preparation of ondansetron gel (F13) 
The gel was prepared by dissolving an accurately weighed 0.5 gram of 
ondansetron powder in a mixture of 5 grams polyethylene glycol 400 
and 1.5 grams polyvinyl pyrrolidone and 50 ml of distilled water using 
a magnetic stirrer. The remaining amount of distilled water required 
to prepare 100 g of the gel was added to the specified amounts of the 
gelling polymer sodium alginate (7% w/w) and soaked overnight for 
complete polymer solvation. The drug mixture was added slowly to 
the previously soaked polymer and continuously stirred to get the 
required gels using magnetic stirrer [9]. 
Transdermal bioavailability study of ondansetron gel in 
experimental animals (rabbits) and human volunteers applying 
UPLC as the analytical tool 
Experimental design 
a. Bioavailability studies in rabbits 
Ondansetron sodium alginate gel (7%w/w) (F13) was selected for 
this study which showed a greater extent of permeation than other 
gels [9]. Marketed I. V. ondansetron (Zofran)®
A parallel design study was selected using nine healthy New Zealand 
rabbits weighing 1.75-2 kg (Animal house of faculty of Medicine, 
Assiut University-Egypt). Rabbits were fasted 12 h before the 
administration of the drug but had free access to water [31] and 
were housed at room temperature. Food was not allowed after drug 
administration [32]. The study protocol was approved and carried 
out according to the animal ethics guidelines of the Ethical Review 
Board of Faculty of Pharmacy, Assiut University Assiut, Egypt (No. 
S7-19).  
 was chosen as the 
reference standard. 
Rabbits were divided randomly into three groups; each group 
consisted of three rabbits, and classified as:  
1. The first group received marketed ondansetron injection Zofran®
2. The second group received the gel formulation of a dose equal to 8 
mg using 0.5 % ondansetron gel). 
 
(8 mg/4 ml, Glaxo) for each rabbit using direct I. V. administration in 
the vein of an ear.  
3. The third group received the gel formulation of a dose equal to 16 
mg using 1 % ondansetron gel). 
The gel formulation was applied on an area of 4x4 cm of rabbit's 
dorsal skin which shaved a day before the experiments. Blood 
samples were collected from the marginal ear vein at time intervals 
0, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3 and 4 h. The acclimation condition of 
animals was good before and after the experimental procedure.  
b. Bioavailability studies in healthy volunteers 
This study was designed to estimate the pharmacokinetic 
parameters of ondansetron gel formulation. The fundamental 
objective was to determine the bioavailability of ondansetron after a 
single application of the gel (8 mg using 0.5% ondansetron gel and 
16 mg using 1% ondansetron gel) behind the ear for 7 h. Secondary 
objectives included determination of local tolerance, safety, and 
tolerability of the gel. An open-label design study was selected, 
wherein 6 healthy subjects (3 males and 3 females) were 
administrated ondansetron gel. The study protocol was approved by 
the Research Ethics Committee at the Faculty of Medicine, Assiut 
University Assiut, Egypt No. 17300082.  
The volunteers were in good health as determined by a physician, 
with a weight of more than 50 kg and a body mass index (BMI) of 
26–31 kg/m2 and they were aged 21-36 y who were non-smoker for 
3 mo. No medical history, physical examination, blood pressure and 
pulse rate findings at baseline were considered clinically relevant. 
All subjects were ready and eligible to participate in the study and 
provided written informed approval. 
Exclusion criteria were: hypersensitivity to similar drugs or 
transdermal systems, taking any medication within 2 w of study 
period, participation in another study within 30 d before receiving 
study medication, clinically significant symptoms in the 3 mo pre-
study, probably need treatment during the study period, presence of 
situations known to intervene with any drug pharmacokinetics, any 
skin conditions at site of application that may block evaluations, a 
history of headaches or subject unlikely to comply with protocol like 
uncooperative attitude [33, 34].  
Volunteers were instructed not to take any other medication 
through the study period. Also, they were advised to avert taking 
baths, exposure to sun or use any cream or oil at application sites of 
the gel [34]. 
Blood sampling 
Serial blood samples of (1-2 ml) were withdrawn before gel 
application and at several time intervals, into a 5-ml screw-capped 
centrifuge tube with K 3
Extraction and analysis of blood samples 
EDTA as anticoagulant [35]. Drug-free 
blood samples were taken from each group before the initiation of 
the treatment. Samples were centrifuged (using Bench-top 
centrifuge, model 3-30K, Sigma, Germany) at 4500 rpm at 4 °C for 
15 min [36]. The clear supernatant (separated plasma) was taken 
away and transferred into a new screw-capped centrifuge tube 
and stored at -20 °C until being analyzed [36, 37].  
The extraction of ondansetron from plasma samples was carried out. 
First, to precipitate proteins a 200 μl of acetonitrile were added to 
200 μl of plasma, then the mixture was vortexed (Vortex Mixer, 
model Fine Vortex, Fine PCR®, Korea) for 2 min and centrifuged at 
10,000 rpm at 4 °C for 20 min and 5 µl of supernatant was filtered 
then injected directly into the UPLC apparatus (AcquityTM
Calibration curve of ondansetron in plasma 
 UPLC, 
Model CHA, Serial # B 15CHA 4326, C18 column of 1.7 µm particle 
size and 2.1x100 mm inner diameter, PDA-e λ Detector, Empower-2 
software, Singapore) with Ultraviolet spectrophotometer (Jenway 
6305 Single Beam spectrophotometer, U. K)for analysis [1]. The 
UPLC analysis was performed on a reversed-phase UPLC system 
using a mobile phase of methanol (70 % v/v) containing ultra-
purified distilled water, with a 0.24 ml/min flow rate at 304 nm 
using UV detector [38, 27, 39]. 
The standard calibration curve of ondansetron in plasma was 
constructed utilizing drug-seven plasma spiked with standard 
ondansetron solutions to get a concentration range from 20-1000 
ng/ml. The spiked plasma was then undergoing the same extraction 
procedure as the samples. Triplicate running was done for each 
standard sample to assess the reproducibility of the detector at each 
concentration. Unknown concentrations of ondansetron were 
calculated from this calibration curve which was obtained by 
plotting various known ondansetron concentrations versus the 
corresponding peak areas. 
Recovery of ondansetron from plasma samples 
Recovery of ondansetron from plasma samples was determined by 
replicate analysis of plasma samples containing known amounts of 
the drug. As in the standard preparation, the samples were spiked to 
the blood and it was extracted, collected in vials and injected into the 
UPLC system. The amount of the drug to be added was calculated as 
well as the amount found was calculated [39].  
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Pharmacokinetic analysis of data 
After measuring the ondansetron concentration in plasma, the 
pharmacokinetic parameters were investigated by analyzing the 
plasma concentration-time data according to the method of 
residuals. The maximum plasma concentration (Cmax) and time to 
reach Cmax (Tmax) were gained directly from the data. Absorption 
rate constant (Ka), absorption half-life (t1/2a), elimination rate 
constant (Kel), elimination half-life (t1/2) and area under the 
ondansetron plasma concentration versus time curve (AUC) were 
computed according to conventional algorithms using the log plasma 
concentration vs. time curve [40]. The elimination half-life (t1/2) was 
computed by dividing 0.693 with Kel 
Common adverse effects assessment 
[40]. 
Adverse effects were observed by the inspectors (local or systemic) 
as well as volunteers were asked to record any things that happened 
during the study. 
Local dermal tolerance evaluation 
Local tolerance was estimated by the inspectors employing a scoring 
system, clinical examination, and registering the appearance of 
adverse effects. The irritation scoring system was as follows: 0 = no 
evidence of irritation, 1= minimal erythema, hardly sensible, 2 = 
specified erythema, easily visible, minimum edema, or minimal 
papular reaction, 3 = erythema and papules, 4 = specified edema, 5 = 
erythema, edema, and papules, 6 =vesicular eruption and 7 = 
powerful reaction at site of application. 
Also, volunteer was asked about the potential manifestation of 
pruritus and burning/stinging feelings, and if recorded, the intensity 
of this reaction was classified from 0 to 3 as follows: 0 = none, 1 = 
mild: some feelings of pruritus/burning, intermittent, without 
consequence on daily activity, 2 = moderate: moderate feelings of 
pruritus/burning, persistent, with some intervention with daily 
activity and 3 = severe: strong pruritus/burning feelings, persistent, 
interfering with daily activity, and/or demanding gel elimination, 
and/or impairing sleep [33]. 
Study of the antiemetic effect of ondansetron gel in cisplatin-
induced emesis in rats 
Experimental animals 
Seventy-two female Albino Wister rats, weighing 160–190 gm 
(Animal house of faculty of Medicine, Assiut University-Egypt), 
adopted to the laboratory environments for 3 d before experiments. 
They were kept under normal conditions of an appropriate humidity 
and temperature and 12 h of light/dark cycle. 
All rats were pliable to free access to kaolin, standard rat chow 
pellets, and water. The standard rat chow and kaolin pellets were 
put in separate containers during the experiment to prohibit their 
blending and to enable the more precise calculation of weight. All 
the experiments were done according to animal ethics guidelines of 
the Ethical Review Board of Faculty of Pharmacy, Assiut University 
Assiut, Egypt (No. S7-19).  
Kaolin pellets were formulated according to the procedure of Mitchell et 
al. (1976) [41]. First, 50 g of pharmaceutical-grade kaolin was added and 
mixed with 1 g of acacia at ratio 50:1 with distilled water to form a dense 
paste. Then, the paste was extruded through a syringe onto wire mesh 
trays to dry at room temperature. After partial drying, pellets of kaolin 
mixture were shaped to resemble the size and volume of the normal 
laboratory diet. The kaolin pellets were set on plastics trays and dried at 
room temperature for up to 48 h [42, 43]. 
Procedures 
Rats were divided randomly into six groups (each group consists of 
twelve rats) and classified as follows: 1 = control group, 2= Blank group 
with ondansetron gel, 3 = Cisplatin group with a dose of 10 mg/kg, 
intraperitoneal (I. P.) daily injection (acute phase), 4 = Cisplatin group 
with a dose of 10 mg/kg I. P. daily injection (acute phase) and 0.5 % 
ondansetron gel twice daily, 5 = Cisplatin group with a dose of 5 mg/kg, I. 
P. injection every 3 d (acute and delayed phase), and 6 = Cisplatin group 
with a dose of 5 mg/kg I. P. injection every 3 d (acute and delayed phase) 
and 0.5 % ondansetron gel twice daily. 
The rats were given individually cisplatin intraperitoneal. The 
dosage of cisplatin was selected to induce dose-limiting emesis 
(acute and delayed) as 10 mg/kg dose to encourage acute emesis, 
which peaked after 2 h, while 5 mg/kg dose induced a biphasic 
profile of emesis; the acute phase began 10 h after cisplatin 
administration, peaked after 12 h and a nadir was attained after 24 
h. The delayed stage was more strong and prolonged than the acute 
phase and attained a peak 48h post cisplatin before gradually 
decreasing in severity during the next 24 h until 72 h post cisplatin, 
at which time a small amount of emesis continued [20, 44].  
One gram of ondansetron gel 0.5 % was dermally applied on an area 
of 2 x 3 cm of rat dorsal skin which shaved in the adaptation days 
before the experiment to animals 12 h before exposure to cisplatin 
and repeated every 12 h. Rats were returned to cages for the 
estimation of daily kaolin, water, and feed intake and body weight 
changes during the next experiment time. 
Kaolin, normal feed and water containers were removed each day at 
the same time and any spillage of them was collected and weighed 
using Digital balance (Precisa, Switzerland) to the nearest 0.01 g, 
food hoppers were then refilled and weighed. The volume of the 
bottle of water was also determined and refilled by fresh tap water. 
The quantity consumed within every 24 h was evaluated by 
matching the weights with the former weights. The following 
equation was applied to determine the ultimate weight value:  
Ultimate weight value (day n) = weight (day n)-weight (day n+1) [45]. 
Statistical analysis 
The differences between experimental groups were analyzed by using 
one-way analysis of variance (ANOVA) and Tukey-Test as a post-hoc test 
or two-way ANOVA followed by post hoc Bonferroni multiple 
comparison test. A probability of less than 0.05 (p<0.05) was considered 
statistically significant. Statistical analysis was executed employing 
Graph-Pad Prism (Graph Pad Prism 6.0, GraphPad, San Diego, CA).  
RESULTS AND DISCUSSION  
Transdermal bioavailability study of ondansetron gel in 
experimental animals (rabbits) and human volunteers applying 
UPLC as the analytical tool 
Plasma samples were analyzed using ultra-performance liquid 
chromatography (UPLC) which is a rapid and sensitive method. This 
assay procedure could be useful for the pharmacokinetic study of 
ondansetron in humans and small animals such as rabbits [35, 38]. 
UPLC is superior to high-performance liquid chromatography 
(HPLC) in achieving a very significant increase in resolution, speed, 
sensitivity and separation efficiency. UPLC gives faster results with 
better resolution, uses less valuable solvents which lower cost and is 
more environmentally friendly than HPLC. 
Calibration curve of ondansetron in plasma 
The standard calibration curve of ondansetron in the rabbit's plasma is 
plotted in (fig. 1a) A straight line was obtained with an excellent 
correlation coefficient (R2 = 0.9998), which re flects good linearity of the 
relationship over the investigated concentration range (50-1000 ng/ml). 
The retention times obtained for ondansetron in the mobile phase and 
rabbit plasma was around 0.93and1.312 min, respectively comparing to 
8-9 min of reported retention time [39]. These chromatography 
conditions con firm the accuracy and reliability of this assay method to 
serve as a practical tool for the analysis of ondansetron in plasma 
samples. (R2 = 0.9998, slope = 42.313, intercept =-0.659) 
The standard calibration curve of ondansetron in human plasma is 
plotted in (fig. 1b) A straight line was obtained with an excellent 
correlation coefficient (R2
Recovery from plasma samples 
 = 0.9993), which reflects good linearity of 
the relationship over the investigated concentration range (20-800 
ng/ml). The retention times obtained for ondansetron in human 
plasma were around 1.55 min. 
The chromatograms show sharp and identifiable peaks. Moreover, 
the ondansetron peaks showed high resolution without interference 
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with the endogenous plasma components. The average recovery of 
ondansetron from spiked plasma samples ranged from 99.4 to 100.7 
%, which reflects good efficiency of the extraction procedure as 
shown in (fig. 2.) 
Bioavailability studies in rabbits 
Based on previous results obtained from ex vivo permeation studies, 
the suitable formulation that selected was ondansetron gel (F13: 
7%w/w sodium alginate) [9]. In this study, the selected formula 
with different concentrations exhibited a slower, but higher extent 
of permeation in four hours than the I. V. application. During the 
study, it was observed that no remarkable signs of any irritation or 
redness at application sites. 
The UPLC method used for the determination of the concentrations 
of ondansetron permeated from skin to the systemic circulation was 






Fig. 1: UPLC calibration curve of ondansetron in (a) rabbit's plasma and (b) human`s plasma 
 
 
Fig. 2: UPLC chromatograms of blank plasma (rabbits and human) spiked with ondansetron at concentration 400 ng/ml 
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From the calibration curve, the plasma drug concentrations were 
determined for each rabbit and the mean plasma drug 
concentrations were calculated, with a standard deviation for each 
treatment group, and the drug concentration-time profiles were 
plotted. The mean plasma concentration-time profiles of 
ondansetron following gel application of the selected formulation 
with different concentrations and IV injection of ondansetron was 
shown in (fig. 3a, b). It could be seen that; the transdermal 
ondansetron (0.5%) gel formula showed plasma detectable 
concentration of (22.833±2.17 ng/m1) after 1/4 h post-treatment 
and the concentration was maintained nearer the reported 
minimum effective concentration (MEC) of ondansetron that it is 30 
ng/ml [46]for more than 2.5 h. While the transdermal ondansetron 
(1%) gel formula showed a plasma detectable concentration of 
(212±38.432 ng/ml) after 1/4 h post-treatment and the 
concentration still detectable for 4 h.  
The plasma drug concentration of transdermal gel formula which 
contains 0.5% ondansetron increased progressively to reach 
maximum concentration Cmax of (116.669±14.418 ng/m1) at Tmax of 
(1.5 h), then decreasing to (13.667±2.082 ng/m1) at 4 h after 
transdermal administration. While, the plasma drug concentration of 
transdermal gel formula which contains 1% ondansetron increased 
progressively to reach maximum concentration Cmax of (373±43.92 
ng/m1) at Tmax
The plasma profile of ondansetron after I. V. administration in the 
rabbits shows the C
 of (1.5 h), and then decreasing to (26.33±5.508 
ng/m1) at 4 h after transdermal administration.  
max:  
Bioavailability studies in healthy volunteers  
311.037±20.518 ng/ml just after injection. 
The plasma concentration decreased to reach (15.743±5.444 ng/ml) 
at 2 h after injection. The pharmacokinetic parameters of 
ondansetron were assessed and listed in tables 1-3. 
Using the calibration curve, the plasma drug concentrations were 
determined for each volunteer and the mean plasma drug 
concentrations were calculated, with a standard deviation for each 
treatment group, and the drug concentration-time profiles were plotted. 
The plasma drug concentrations of ondansetron were represented in 
(fig. 4) It could be seen that; the transdermal gel containing 
0.5%ondansetron showed a plasma detectable concentration of 
(419.55±2.17 ng/ml) after 1-h post-treatment and the concentration 
was maintained above the reported minimum effective concentration 
(MEC) for ondansetron that it is 30 ng/ml [46] for more than 7 h. 
  
 
a- Gel F13 of 8 mg dose 
 
 
b- Gel F13 of 16 mg dose 
Fig. 3: Mean plasma concentration-time profile of ondansetron after administration of gel formula (F13) of (a) 8 mg dose (b) 16 mg dose 
as compared to the marketed I. V. injection 
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Fig. 4: Mean plasma concentration–time profiles following administration of ondansetron gel F13 0.5% (8 mg) in males and females 
 
Table 1: Pharmacokinetics parameters (a) of ondansetron I. V. administration of Zofran®
Pharmacokinetics 
 and the gel formula F 13 to rabbits (8 mg/dose) 
parameter 
Marketed I. V. ondansetron  
(a) (8 mg/dose) 
Transdermal gel F13 
(8 mg/dose) 
P value Significance of the difference(c) 
Cmax 311.037±20.518  (ng/ml) 117.168±4.603 0.001 *** 
T max 0 (h) 1.5 0.001 *** 
Ka (h-1 ----- ) 1.844±0.019 ----- ----- 
t1/2a -----  (h) 0.376±0.004 ----- ----- 
Kel (h-1 1.255±0.079 ) 1.176±0.221 0.05 NS 
t1/2el 0.553±0.035  (h) 0.605±0.152 0.05 NS 
AUC 0-∞ 0.303±0.039 (µg. h/ml) 0.22±0.022 0.05 NS 
AUMC 0-∞ (µg. h2 0.249±0.048 /ml) 0.413±0.099 0.05 NS 
MRT0-∞ 0.816±0.055 (h) 1.78±0.152 0.001 *** 
ClT 26.686±3.303  (L/h) 36.529±3.615 <0.05 * 
Vd 21.217±1.409 (liter) 31.725±3.83 <0.01 ** 
F (%) ----- 73.01±5.124  ----- 
amean±SD (n = 3), bCmax:  maximum plasma concentration, Tmax:  time to reach Cmax, Ka:  absorption rate constant, t1/2a:  absorption half-life, Kel:  
elimination rate constant, t1/2: elimination half-life, AUC: area under the ondansetron plasma concentration versus time curve, AUMC: area under 
the moment vs. time curve, MRT: mean residence time, Cl: clearance, Vd:  volume of distribution, F: fraction absorbed (bioavailability). c
 
highly 
significant *** p 0.001, moderate significant ** p 0. 01, mild significant * p 0.05, non-significant NS p>0.05 
Table 2: Pharmacokinetics parameters (a) of ondansetron I. V. administration of Zofran®
Pharmacokinetics 
and the gel formula F13 to rabbits (16 mg/dose) 
parameter 
Marketed I. V. ondansetron  
(a) (8 mg/dose) 
Transdermal gel F13 
(16 mg/dose) 
P-value Significance of the difference (c) 
Cmax 311.037±20.518  (ng/ml) 360.833±24.168 <0.05 * 
T max 0 (h) 1.5 0.001 *** 
Ka (h-1 ----- ) 2.022±0.049 ----- ----- 
t1/2a -----  (h) 0.343±0.008 ----- ----- 
Kel (h-1 1.255±0.079 ) 1.065±0.068 0.05 * 
t1/2el 0.553±0.035  (h) 0.657±0.05 0.05 * 
AUC 0-∞ 0.303±0.039 (µg. h/ml) 0.721±0.044 0.001 *** 
AUMC 0-∞ (µg. h2 0.249±0.048 /ml) 1.089±0.109 0.001 *** 
MRT0-∞ 0.816±0.055 (h) 1.503±0.051 0.001 *** 
ClT 26.686±3.303  (L/h) 22.32±1.2 >0.05 NS 
Vd 21.217±1.409 (liter) 20.989±0.286 >0.05 NS 
F (%) ----- 261.398±16.091  ----- 
amean±SD (n = 3), bCmax:  maximum plasma concentration, Tmax:  time to reach Cmax, Ka:  absorption rate constant, t1/2a:  absorption half-life, Kel:  
elimination rate constant, t1/2: elimination half-life, AUC: area under the ondansetron plasma concentration versus time curve, AUMC: area under 
the moment vs. time curve, MRT: mean residence time, Cl: clearance, Vd:  volume of distribution, F: fraction absorbed (bioavailability)c
 
highly 
significant *** p 0.001, moderate significant ** p 0. 01, mild significant * p 0.05, non-significant NS p>0.05. 
Fathallah et al. 
Int J Pharm Pharm Sci, Vol 12, Issue 3, 68-82 
74 
Table 3: Pharmacokinetics parameters(a)
Pharmacokinetics 
 of ondansetron gel formula F13 with different doses (8 and 16 mg) to rabbits 
parameter 
Transdermal gel F 13 
(a) (8 mg dose) 
Transdermal gel F 13 
(16 mg dose) 
P value Significance of the difference(c) 
Cmax 117.168±4.603  (ng/ml) 360.83±24.17 0.001 *** 
T max 1.5 (h) 1.5 >0.05 Ns 
Ka (h-1 1.844±0.019 ) 2.022±0.049 <0.01 ** 
t1/2a 0.376±0.004  (h) 0.343±0.008 <0.01 ** 
Kel (h-1 1.176±0.221 ) 1.065±0.068 <0.05 * 
t1/2el 0.605±0.152  (h) 0.657±0.05 <0.05 * 
AUC 0-∞ 0.22±0.022 (µg. h/ml) 0.721±0.044 0.001 *** 
AUMC 0-∞ (µg. h2 0.413±0.099 /ml) 1.089±0.109 0.001 *** 
MRT0-∞ 1.78±0.152 (h) 1.503±0.051 <0.05 * 
ClT 36.529±3.615  (L/h) 22.32±1.2 <0.01 ** 
Vd 31.725±3.83 (liter) 20.989±0.29 <0.01 ** 
F (%) 73.01±5.124 261.398±16.1  ----- 
amean±SD (n = 3), bCmax:  maximum plasma concentration, Tmax:  time to reach Cmax, Ka:  absorption rate constant, t1/2a:  absorption half-life, Kel:  
elimination rate constant, t1/2: elimination half-life, AUC: area under the ondansetron plasma concentration versus time curve, AUMC: area under 
the moment vs. time curve, MRT: mean residence time, Cl: clearance, Vd:  volume of distribution, F: fraction absorbed (bioavailability)c
 
Each pharmacokinetic value was compared between men and 
women. Women consistently had significantly higher mean 
residence time (MRT) and elimination half time than men and the 
drug remained in higher value in women at 7 h post-application than 
men. While there is no significant differences were detected 
between genders in AUC for ondansetron gel. 
Maximal plasma concentrations of ondansetron were attained after 
3 h. of application of an average of 617.22 ng/ml. The plasma drug 
concentration of ondansetron (0.5%) gel increased progressively to 
reach maximum concentration C
highly 
significant *** p 0.001, moderate significant ** p 0. 01, mild significant * p 0.05, non-significant NS p>0.05 
max of (690.27±57.75 ng/m1) at 
Tmax of (3 h) for men and Cmax of (546.92±70 ng/m1) at Tmax
In general, the dermal evaluation showed that ondansetron gel 
was fully tolerated and a total rating of skin irritation was very 
low. In the plurality of assessments, Grade 0 (none) was observed. 
Common adverse effects were headache, back pain and dizziness 
for all volunteers and one subject suffer from the metallic taste. 
There are no serious adverse effects were considered treatment-
related. 
 of (3.5 
h) for women, then decreasing to (61.3±14 ng/m1 and 178.75±22.5 
ng/m1) at 7 h after transdermal administration for men and women, 
respectively as presented in table 4.  
Linearizing the ondansetron plasma concentration data using 
semi-log graph scale 
By plotting the intravenous plasma concentration data onto the 
semi-log graph scale, we can obtain a straight line which indicates 
the elimination phase and the drug occupies one compartment 
pharmacokinetics (40) as shown in fig. 5a. While in case of 
extravascular dose (transdermal gel) the two processes of 
absorption and elimination occur in parallel and at late times in 
graphs, absorption may be complete and we see virtually clear 
elimination phase (47) as shown in fig. 5 b, c, and d 
  
Table 4: Pharmacokinetics parameters (a)
Pharmacokinetics 






P-value Significance of the difference (c) 
Cmax 690.27±0.065  (ng/ml) 522.65±0.098  >0.05 Ns 
T max 3  (h) 3.5  >0.05 Ns 
Ka (h-1 0.893±0.050  ) 0.70±0.043 <0.01 ** 
t1/2a 0.779±0.043  (h) 0.994±0.061 <0.01 ** 
Kel (h-1 0.732±0.07 ) 0.357±0.148 0.05 * 
t1/2el 0.955±0.091  (h) 2.343±0.972 >0.05 Ns 
AUC 0-∞ 3.333±0.468 (µg. h/ml) 3.176±0.071 >0.05 Ns 
AUMC 0-∞ (µg. h2 11.65±1.93 /ml) 15.65±3.184 >0.05 Ns 
MRT0-∞ 3.483±0.090 (h) 4.952±1.113 >0.05 Ns 
ClT 2.801±0.96  (L/h) 2.705±0.155 >0.05 Ns 
Vd 5.606±0.956 (liter) 6.477±0.155 >0.05 Ns 
amean±SD (n = 3), bCmax:  maximum plasma concentration, Tmax:  time to reach Cmax, Ka:  absorption rate constant, t1/2a:  absorption half-life, Kel:  
elimination rate constant, t1/2: elimination half-life, AUC: area under the ondansetron plasma concentration versus time curve, AUMC: area under 
the moment vs. time curve, MRT: mean residence time, Cl: clearance, Vd:  volume of distribution, F: fraction absorbed (bioavailability). c
 
highly 
significant *** p 0.001, moderate significant ** p 0. 01, mild significant * p 0.05, non-significant NS p>0.0 
The antiemetic effect of ondansetron gel in cisplatin-induced 
emesis in rats 
American Society of Clinical Oncology guidelines classified cisplatin 
as the highest emetic risk group as it causes acute and delayed 
vomiting [19]. Acute vomiting mainly occurs within a few minutes to 
several hours next to cisplatin administration and usually resolves 
within the first 24 h. Delayed vomiting develops after 24 h next to 
cisplatin administration and continues for 6-7 d [20]. 
Signs and mortality rates detected due to cisplatin injection in 
rats and the effect of ondansetron gel 
All groups received cisplatin of 5 mg/kg dose suffered from most 
common side effects caused by it as general drowsiness, fatigue, 
loss of appetite and low locomotor activity like horizontal 
movement, mobility, and rearing during first 24 h after injection 
[48]. This result is in agreement with Malik et al. [49] who 
reported the influence of cisplatin on locomotors activity on rats 
after administration of 6 mg/kg cisplatin on day 2 post-injection 
compared to control group. They suggested that the lowering in 
locomotor activity might be a primary influence of cisplatin [50] 
or secondary to “nausea” or visceral malaise; the decrease in 
food intake might be attributed to nausea or to a reduction in 
locomotor activity. 
From day 3-5 the feces of the cisplatin group was constipated grey in 
color compared with the control group, and on day 5 the feces 
become black and soft and convert to dark watery diarrhea in late 
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days before the death of rats. Also, the rats suffering from 
nosebleeds and red spots on the skin of the head, neck and lower 
parts of legs due to reducing the number of platelets, alopecia, dry 
skin and dehydration. Also, there are muscle weakness and paralysis 
leading to death within 24 h. 
About 25 % of rats receiving cisplatin without ondansetron gel died 
at day 5 of experiment and 100 % of this group died at day 7 of the 
experiment, while another group which receiving cisplatin and 
ondansetron gel began to die at day 6 and 50 % of rats still alive up 
to day 15 of the experiment. 
Also, the previous signs also observed in the groups receiving 
cisplatin of 10 mg/kg dose but more aggressive and accelerated after 
day 3 of the experiment and all rats died on days 4 and 5. While, the 
blank group receiving ondansetron gel did not show any specific 
signs like irritation, redness, drowsiness or fatigue and preserves 
the same activity comparing to the control group. 
 
 
a-I. V. injection of 8 mg dose 
 
b-Transdermal gel F13 of 8 mg dose in rabbits 
 
c-Transdermal gel F13 of 16 mg dose in rabbits 
 
d-Transdermal gel of F13 of 8 mg dose in humans 
Fig. 5: Semi-log plot of ondansetron plasma concentration against time curve following administration of (a) marketed I. V. injection, (b) 
transdermal administration of 8 mg dose in rabbits, (c) transdermal administration of 16 mg dose in rabbits and (d) transdermal 
administration of 8 mg dose in humans 
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Effect of ondansetron on cisplatin-induced body weight loss 
Cisplatin produced hypophagia and weight loss in all rats but these 
symptoms of illness were less severe in rats which had been 
administrated ondansetron gel than those did not have [51].  
The results show that the body weight loss was increased in a dose-
dependent manner, as the higher cisplatin tested dose (10 mg/kg); 
rats show more weight loss compared to smaller dose and these 
results are in good harmony with data obtained by Cabezos et al. [52]. 
The two groups receiving cisplatin injection induce significant 
loss of animal's body weight of about 13.43 and 18 % for 5 and 
10 mg/kg doses, respectively at day 5 of an experiment 
comparing to 7.89 and 14.75 % for groups receiving 
ondansetron gel (p ˂  0.05).  
Also, the groups receive 5 mg/kg cisplatin induces significant loss of 
animal's body weight of about 17.36 % for 7 d of an experiment 
compared to 10.6 % for ondansetron gel group receiving (p˂  0.001) 
as demonstrated in tables 5-6 and (fig. 6a, b, c, and d). 
 
Table 5: Effect of ondansetron gel formulation (F13) on body weight change (grams) of rats administered cisplatin (5 mg/kg, i. p.) 
Days Control Control+ondansetron gel Cisplatin (5 mg/kg) I. P. Cisplatin (5 mg/kg) I. P. +ondansetron gel 
0 186.4 2±1.66 185.10±1.15 183.67±3.79 184.95±2.92 
1 181.33±1.24 179.69±1.15 180.4 8±1.50 184.09±3.82 
2 179.52±1.16 181.42±1.67 176.33±1.15 180.10±3.02 
3 180.84±2.16 180.71±1.86 170.02±2.11 180.21±3.11c 
4 
*** 
181.22±2.64 178.57±3.50 167.63±0.55 176.89±2.85c 
5 
*** 
182.32±1.82 182.43±1.68 159.08±1.81 170.34±2.41c 
6 
c,*** 
183.50±2.29 180.08±2.13 157.42±4.88 164.74±2.69c 
7 
c,** 
181.59±4.13 180.59±2.90 151.77±2.92 165.29±2.36c 
8 
c,*** 
185.33±2.52 182.09±2.14 Died 162.50±1.32
9 
c 
184.23±2.25 184.93±2.03 Died 161.30±3.93c 
aP<0.05, bP<0.01, c P<0.001 vs. control group, *P<0.05, **P<0.01, ***
 
P<0.001 vs. cisplatin group. 
Table 6: Effect of ondansetron gel formulation (F13) on body weight change (grams) of rats administered cisplatin (10 mg/kg, i. p.) 
Days Control Cisplatin (10 mg/kg) I. P. Cisplatin (10 mg/kg) I. P. +ondansetron gel 
0 186.42±1.66 184.18±4.06 184. 98±1.36 
1 181.33±1.24 176.2 6±3.33 179.07±2.07 
2 179.52±1.16 164.44±5.09 169.34±1.12c 
3 
c 
180.84±2.16 158.74±4.03 165.24±0.96c 
4 
c,* 
181.22±2.64 153.78±2.86 163.90±1.33c 
5 
c,*** 
182.32±1.82 151.02±3.02 157.68±1.71c c,* 
aP<0.05, bP<0.01, c P<0.001 vs. control group, *P<0.05, **P<0.01, ***
 
P<0.001 vs. cisplatin group. 
 
a-After administration of cisplatin (5 mg/kg, i. p.) 
 
b-After administration of cisplatin (10 mg/kg, i. p.) 
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c- After 5 d of the experiment 
 
d-After 7 d of the experiment 
Fig. 6: Effect of ondansetron gel formulation (F13) on body weight change of rats (a) administered cisplatin (5 mg/kg, i. p.), (b) 
administered cisplatin (10 mg/kg, i. p.), (c)after 5 d of the experiment and (d) after 7 d of the experiment 
 
Effect of ondansetron on the nutrition profile of cisplatin 
treating rats 
Water consumption 
After adaptation period, control rats consume daily amount of 
23.46±5 ml of water and intraperitoneal administration of cisplatin 
(5 mg/kg) make a significant decrease in daily water consumption to 
average 11.8±7.8 ml except at day 2 and3 the results show 
increasing in water consumption due to the nephrotoxicity which is 
a current side effect of cisplatin treatment [53] and increased water 
intake has been noted in several studies [51]. 
These results are in good consent with De Jonghe et al. [51] who 
found that kaolin consumption ameliorates cisplatin-induced 
reductions in food but not water intake. This might be explained by 
the different mechanisms that underlie food and water transit and 
absorption in the gut. While the daily water amount consumed by 
rats significantly elevated to about 21.17±4.7 by using ondansetron 
gel comparing with cisplatin only (p ˂ 0.05) as shown in (fig. 7a) and 
table 7. 
Intraperitoneal administration of cisplatin of a dose (10 mg/kg) 
make a significant decrease in daily water consumption to average 
7±11.5 ml in nearly all days and the using of ondansetron gel 
significantly elevate the volume of water consumed by rats to 
11.6±8.7 (p ˂ 0.05) as elucidated in (fig.  7b) and table 8 and this 
result is in agreement with Liu et al. [44] who reported that the 
using dose of cisplatin more than 5 mg/kg cause increase in gastric 
contents as well as decreased food and water intake at 48 h post-
cisplatin treatment. Further support by the studies of Bradner and 
Schurig [54] and Olver et al. [55] in mice showing a dose-related 
decrease in water intake due to an increase in the weight of gastric 
contents measured at 24 or 48 h after cisplatin. This effect was 
obtained with other cytotoxic anticancer drugs in mice and rats [56]. 
  
Table 7: Effect of ondansetron gel formulation (F13) on the change of water consumption (ml) induced by cisplatin (5 mg/kg, i. p.) 
Days Control Control+ondansetron gel Cisplatin (5 mg/kg) I. P. Cisplatin (5 mg/kg) I. P. +ondansetron gel 
0 26.75±2.75 28.42±2.27 27.50±2.50 26.00±3.00 
1 30.50±2.63 35.00±7.00 15. 50±1.50 20. 00±2.00c 
2 
c 
22. 75±2.25 31.42±6.50 27.00±3.00 21.00±2.00
3 
* 
25.25±2.50 29.92±10.0 26. 33±3.51 25.83±2.02 
4 27.75±4.88 28.58±6.50 9. 33±3.25 25.17±1.76c 
5 
*** 
25. 75±1.75 34.42±9.50 4.00±2.00 16.67±2.02
6 
c,** 
20.33±1.53 29.44±0.51 5.50±2.18 18.67±2.52 c 
7 
*** 
14.33±1.53 28.64±0.56 4.00±0.50 29.00±3.00c 
8 
*** 
21.17±1.76 30.72±1.11 Died 17.00±2.00 
9 20.00±2.00 29.67±4.73 Died 15.00±2.50 
aP<0.05, bP<0.01, c P<0.001 vs. control group, *P<0.05, **P<0.01, ***P<0.001 vs. cisplatin group. 
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a-cisplatin (5 mg/kg, i. p.) 
 
b-cisplatin (10 mg/kg, i. p.) 
Fig. 7: Effect of ondansetron gel formulation (F13) and (a) cisplatin (5 mg/kg, i. p.) and (b) cisplatin (10 mg/kg, i. p.) on water 
consumption (ml) in rats 
 
Table 8: Effect of ondansetron gel formulation (F13) on the change of water consumption (ml) induced by cisplatin (10 mg/kg, i. p.) 
Days Control Cisplatin (10 mg/kg) I. P. Cisplatin (10 mg/kg) I. P. +ondansetron gel 
0 26.75±2.75 31.50±2.50 30.00±3.50 
1 30.50±2.63 1.67±0.58 9.17±0.76c 
2 
c,** 
22.75±2.25 5.00±1.32 16.17±2.02c 
3 
a,*** 
25.25±2.50 1.33±2.31 14. 17±2.84c 
4 
c,*** 
27.75±4.88 2.00±2.65 12.83±1.76c 
5 
c,*** 
25.75±1.75 0.33±0.58 13. 50±3.12c c,*** 
aP<0.05, bP<0.01, c P<0.001 vs. control group, *P<0.05, **P<0.01, ***
 
P<0.001 vs. cisplatin group. 
Food consumption 
Tables 9-10 and (fig. 8a, b) showed that after injection of cisplatin, 
normal feed consumption in the cisplatin groups significantly 
decreased when compared with the control group after 24 h of 
injection (P<0.01). Moreover, this decrease was reduced by 
ondansetron administration after the third day of injection (P<0.05) 
in the case of 5 mg/kg cisplatin dose. Similarly, in case of 10 mg/kg 
cisplatin dose, there is slight attenuation of food intake by using 
ondansetron gel comparing with cisplatin group and these results 
are in harmony with data obtained by Cabezos et al. [52] who 
reports that administration of cisplatin prompted a significant 
decrease in food ingestion in the 24 h instantly after administration 
due to severe anorexia. 
Kaolin consumption 
In case of 5 mg/kg dose of cisplatin, there is a significant increase in 
kaolin consumption during first 48 h after injection and the changes 
in of kaolin intake were remarkably recovered on day 3, although 
the body weight loss was still preserved as demonstrated in table 11 
and (fig. 9a). 
Further administration of cisplatin did not change the kaolin 
consumption and still maintained at the normal level. This explains 
the change of quality of rats feces during the experiment period as 
cisplatin produces gastric stasis and diarrhea [49, 57, 58] and clay 
possesses toxin-binding properties [59, 60] as an anti-diarrhea drug 
[61]. Thus, kaolin consumption could limit the side effects of 
cisplatin on the GI tract, lessening the severity of distress 
experienced by the animal. Pre-treatment with the ondansetron gel 
significantly reduced the cisplatin-induced increase in kaolin 
consumption to the normal levels. 
While in the case of 10 mg/kg dose of cisplatin the level of kaolin 
was increased significantly on day 4 (p˂0 .001) comparing to both 
control and ondansetron group as elucidated in table 12 and (fig. 
9b). Delayed access of rats to kaolin may be one of the reasons for 
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rapid death due to increasing the severity of illness symptoms like 
weight loss and hypophagia. These data suggest that kaolin 
consumption following cisplatin not only indicates sickness but also 
plays a therapeutic role by diminishing the degree of malaise 
experienced by the rat and/or enhancing the rate of recovery as 
reported by Riezzo G, et al. [58].  
Effect of ondansetron gel alone on rats 
There is no significant difference in changing in body weight and 
water, food, and kaolin consumption comparing with the control 
group as shown in (fig. 6a, 7a, 8a, and 9a) and tables 5, 7, 9 and 11. 




a- cisplatin (5 mg/kg, i. p.) 
 
b- cisplatin (10 mg/kg, i. p.) 
Fig. 8: Effect of ondansetron gel formulation (F13) and (a) cisplatin (5 mg/kg, i. p.) and (b) cisplatin (10 mg/kg, i. p.) on food consumption 
(grams) in rats 
 
Table 9: Effect of ondansetron gel formulation (F13) on the change of food consumption (grams) induced by cisplatin (5 mg/kg, i. p.) 
Days Control Control+ondansetron gel Cisplatin (5 mg/kg) I. P. Cisplatin (5 mg/kg) I. P. +ondansetron gel 
0 15.99±1.97 13.63±0.03 15.92±2.98 13.04±1.56 
1 15.15±3.12 18.30±7.66 4.14±0.68 5.56±0.59 c 
2 
a 
13.07±2.89 14.43±5.50 1.90±1.01 3.44±0.43 c 
3 
c 
10.98±3.92 8.18±0.17 1.42±1.32 3.41±0.41 c 
4 
c 
12.66±1.85 8.32±0.91 0.36±0.25 4.63±0.61 c 
5 
c*, 
12.33±0.70 10.11±0.10 0.24±0.02 3.80±0.35 c 
6 
c,* 
13.42±0.14 10.70±1.12 0.01±0.01 3.78±0.48 c 
7 
c 
10.160±1.62 11.51±1.39 0.18±0.28 4.55±0.55 c 
8 
c,* 
12.400±2.44 12.60±0.35 Died 4.54±0.55 
9 
c,** 
14.210±2.08 12.33±1.53 Died 4.00±0.50 c,* 
aP<0.05, bP<0.01, c P<0.001 vs. control group, *P<0.05, **P<0.01, ***P<0.001 vs. cisplatin group. 
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Table 10: Effect of ondansetron gel formulation (F13) on the change of food consumption (grams) induced by cisplatin (10 mg/kg, i. p.) 
Days Control Cisplatin (10 mg/kg) I. P. Cisplatin (10 mg/kg) I. P. +ondansetron gel 
0 15.99±1.97 15.40±2.94 14.21±1.21 
1 15.15±3.12 5.85±0.93 9.40±0.96c 
2 
c 
13.07±2.89 2.09±0.21 6.45±0.48c 
3 
c,* 
10.98±3.92 0.07±0.12 1.78±0.20c 
4 
c 
12.66±1.85 0.33±0.58 2.03±0.95c 
5 
c 
12.33±0.70 0.50±0.50 3.60±0.96c c 
aP<0.05, bP<0.01, c P<0.001 vs. control group., *P<0.05, **P<0.01, ***
 
P<0.001 vs. cisplatin group. 
 
a-cisplatin (5 mg/kg, i. p.) 
 
b-cisplatin (10 mg/kg, i. p.) 
Fig. 9: Effect of ondansetron gel formulation (F13) and (a) cisplatin (5 mg/kg, i. p.) and (b) cisplatin (10 mg/kg, i. p.) on the Kaolin 
consumption (grams) in rats 
 
Table 11: Effect of ondansetron gel formulation (F13) on the change of Kaolin consumption (grams) induced by cisplatin (5 mg/kg, i. p.) 
Days Control Control+ondansetron gel Cisplatin (5 mg/kg) I. P. Cisplatin (5 mg/kg) I. P. +ondansetron gel 
0 0.25±0.02 0.08±0.08 0.21±0.06 0.24±0.07 
1 0.28±0.12 0.18±0.01 1.59±0.40 0.01±0.02c 
2 
*** 
0.25±0.05 0.20±0.02 0.97±0.35 0.02±0.03c 
3 
*** 
0.27±0.02 0.29±0.04 0.11±0.10 0.03±0.03 
4 0.15±0.15 0.20±0.02 0.13±0.12 0.29±0.12 
5 0.21±0.11 0.22±0.02 0.22±0.03 0.18±0.03 
6 0.24±0.10 0.34±0.04 0.20±0.09 0.24±0.04 
7 0.17±0.15 0.14±0.13 0.20±0.10 0.20±0.04 
8 0.10±0.05 0.14±0.01 Died 0.04±0.05 
9 0.24±0.10 0.26±0.10 Died 0.18±0.03 
aP<0.05, bP<0.01, c P<0.001 vs. control group, *P<0.05, **P<0.01, ***P<0.001 vs. cisplatin group. 
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Table 12: Effect of ondansetron gel formulation (F13) on the change of Kaolin consumption (grams) induced by cisplatin (10 mg/kg, i. p.) 
Days Control Cisplatin (10 mg/kg) I. P. Cisplatin (10 mg/kg) I. P. +ondansetron gel 
0 0.25±0.05 0.23±0.06 0.35±0.08 
1 0.28±0.17 0.19±0.05 0.28±0.03 
2 0.25±0.05 0.30±0.09 0.33±0.58 
3 0.27±0.02 0.63±0.55 0.14±0.06 
4 0.18±0.19 1.82±0.33 0.28±0.07c 
5 
*** 
0.21±0.21 1.96±0.44 0.36±0.02c *** 
aP<0.05, bP<0.01, c P<0.001 vs. control group, *P<0.05, **P<0.01, ***
 
P<0.001 vs. cisplatin group. 
CONCLUSION 
Based on the high efficacy of transdermal ondansetron gel (7%w/w 
sodium alginate) on the emesis induced by antineoplastic drugs and 
long-term efficiency, as well as a high bioavailability, the 
transdermal ondansetron gel could be a promising convenient 
system to relieve, prohibit or stop nausea and vomiting in patients 
taking chemotherapy or radiotherapy. 
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